Brief: Hansa Biopharma, Genethon Announce Collaboration To Develop Imlifidase As Pre-Treatment To Gene Therapy In Crigler-Najjar Syndrome Patients With Anti-AAV Antibodies
27/04/2023 16:46
April 27 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA AND GENETHON ANNOUNCE COLLABORATION TO
DEVELOP
IMLIFIDASE AS PRE-TREATMENT TO GENE THERAPY IN CRIGLER-NAJJAR
SYNDROME PATIENTS WITH ANTI-AAV ANTIBODIES
Source text for Eikon: ID:nPn1zfzHDa
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS